Speaking at Amgen One, Associate Professor Simon Harrison, Lead for the CAR T-cell Clinical Program at the Peter MacCallum Cancer Centre gave delegates an update on chimeric antigen receptor (CAR) T-cells and bispecific T-cell engagers (BiTEs) for multiple myeloma (MM). “Given the myeloma microenvironment is highly immunoactive, redirecting T-cells to fight the patient’s own cancer ...
How well do you know your BiTEs from your CAR-Ts?
Sponsored by Amgen Australia Pty Ltd
7 May 2019